Clinical Trial Update: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Zipalertinib versus placebo as adjuvant therapy for Stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zipalertinib (Zipalertinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: NSCLC, Stage IB-IIIA, Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING